MedTrace Logo

Obstetrical History and Anti-HLA Antibodies Level

NCT06021925 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 6000

Last updated 2024-01-24

No results posted yet for this study

Summary

Chronic histiocytic intervillositis (CHI) is associated with severe and recurrent obstetrical complications. A link between anti-HLA Antibodies (Ab) and CHI has recently been established. At the Etablissement Français du Sang (EFS), donors who have already given birth once and have high levels of anti-HLA are excluded from donating apheresis platelets and therapeutic plasma to prevent TRALI (Transfusion Related Acute Lung Injury). No studies have examined the obstetrical history of these donors. The question is: is there an association between anti-HLA levels and obstetrical complications?

Conditions

  • Blood Donors
  • Anti-HLA Antibody

Interventions

OTHER

Obstetrical history

Selection of donors by EFS retrospectively on the basis of inclusion criteria. Information note sent by e-mail, non-opposition as well as a questionnaire to be completed online to obtain data on obstetrical history.

OTHER

Anti-HLA Antibody tests

Analyze responses in relation to the results of the anti-HLA Antibody tests performed at the time of donation.

Sponsors & Collaborators

  • Etablissement Français du Sang (Nouvelle Aquitaine)

    collaborator UNKNOWN

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Xavier LAFARGE, Doctor · Etablissement Français du Sang (Nouvelle Aquitaine)

  • Alexandra BENACHI, Professor · APHP, Antoine Béclère Hospital, CLAMART, France

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-13
Primary Completion
2024-06-13
Completion
2024-06-13

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06021925 on ClinicalTrials.gov